FindTrial
Sign In

Selectively Regulating and Controlling Effect of Jiedu-quyu-ziyin therapeutic methods on Estrogen Receptor Subtypes in Lymphocytes of Systemic Lupus Erythematosus

Selectively Regulating and Controlling Effect of Jiedu-quyu-ziyin therapeutic methods on Estrogen Receptor Subtypes in Lymphocytes of Systemic Lupus Erythematosus

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-12002009
Enrollment
Unknown
Registered
2012-03-13
Start date
2011-02-07
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic lupus erythematosus

Interventions

Lupus:None

Sponsors

Zhejiang University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 30 Years

Inclusion criteria

Inclusion criteria: Fit to SLICC 2009 modified ACR systemic lupus erythematosus (sle) classification standard; fit to TCM syndrome of kidney Yin deficiency, toxic heat and blood stasis; Disease moderate activities (SLEDAI between 10 to 14); female patients at the age of 20 to 30 years old; menstrual cycle to normal; did not accept the traditional Chinese medicine and hormone replacement therapy within one month, patients who volunteered to take the test and sign the informed agreement.

Exclusion criteria

Exclusion criteria: Pregnancy or merge the other diseases

Design outcomes

Primary

MeasureTime frame
estrogen receptor alpha/beta in heral blood lymphocyte;—

Countries

China

Contacts

Public ContactWen Chengping
wengcp@163.com+86 0571 86613644

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026